ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Emerald picks Lonza for cannabinoid synthesis

by Rick Mullin
February 17, 2019 | APPEARED IN VOLUME 97, ISSUE 7

 

Emerald Health Pharmaceuticals has signed Lonza to make a synthetic derivative of cannabidiol it is developing to treat multiple sclerosis and systemic scleroderma. Under the contract, Lonza will synthesize the active pharmaceutical ingredient (API), VCE-004.8, and finished liquid-filled hard and soft-gel capsules. Lonza will make the API in Nansha, China; hard capsules in Edinburgh, Scotland; and soft gels in Ploermel, France. The agreement allows for further commercialization of novel cannabinoids.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment